The British medical device maker said that some 95.4% of the shareholders affected by the tie-up voted for the deal, with 4.6% of those shares voting against. Overall, the votes to approve the merger amounted to 62.4% of total BTG shares and the votes against were 0.03%, BTG said.
Earlier this week Marlborough, Mass.-based Boston Scientific said it closed a $4.3 billion debt round it plans use to defray the cost of buying BTG.
The £8.40-per-share offer, worth about $4.24 billion (£3.3 billion), is slated to close in mid-2019. The purchase price is a 36.6% premium over BTG’s closing price the day before the Nov. 20 announcement and a 51.0% premium over the stock’s 90-day volume-weighted average price.
BTG’s largest division makes devices for oncology and vascular conditions; the company also makes overdose and antivenin drugs for snakebite.
At DeviceTalks Boston, Tyler Shultz will give attendees an inside look at Theranos and how he was able to sound the alarm after he realized the company was falling apart. Shultz will take attendees behind the story that everyone is talking about: the rise and fall of Elizabeth Holmes and her diagnostic company, Theranos.
Join Shultz and 1,000+ medical device professionals at the 8th annual DeviceTalks Boston.